Fibrobiologics Inc

FibroBiologics unveils a cutting‑edge thymic organoid platform that could rejuvenate immune function—while trimming costs to fuel research and attract pharma partners.

Fibrobiologics Inc. raises $1.5 M in a direct offering to fund fibroblast therapies for degenerative disc disease, MS, cancer and more, amid a brief stock dip and cautious market sentiment.